Search results for "Clinical Practice"

showing 10 items of 401 documents

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice

2017

Background: Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at the recommended dose and schedule of 160 mg once daily for the first 3 weeks of each 4-week cycle. However, it has a relevant toxicity profile that mainly occurs within the first cycles of therapy, and dose and schedule adjustments are often required to reduce the frequency or severity of adverse events and to avoid early treatment discontinuation. To date, large amounts of data on the use of REG in metastatic GIST patients in daily clinical practice are not available, and we lack information about how this treatment personalization really a…

0301 basic medicineOncologymedicine.medical_specialtyScheduleStromal cellSettore MED/06 - Oncologia Medicalcsh:RC254-282PersonalizationNO03 medical and health scienceschemistry.chemical_compound0302 clinical medicinetyrosine kinase inhibitorQuality of lifeInternal medicineRegorafenibtyrosine kinase inhibitorsmedicineOriginal Researchreferral centresGiSTbusiness.industryGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitors; OncologyGastrointestinal stromal tumourslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenspersonalized treatmentClinical PracticeGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitorsreferral centre030104 developmental biologychemistryquality of lifeOncology030220 oncology & carcinogenesisregorafenibbusinessGIST personalized treatment quality of life referral centres regorafenib tyrosine kinase inhibitorsGIST
researchProduct

Microcephaly/Trigonocephaly, Intellectual Disability, Autism Spectrum Disorder, and Atypical Dysmorphic Features in a Boy with Xp22.31 Duplication

2019

The Xp22.31 segment of the short arm of the human X chromosome is a region of high instability with frequent rearrangement. The duplication of this region has been found in healthy people as well as in individuals with varying degrees of neurological impairment. The incidence has been reported in a range of 0.4-0.44% of the patients with neurological impairment. Moreover, there is evidence that Xp22.31 duplication may cause a common phenotype including developmental delay, intellectual disability, feeding difficulty, autistic spectrum disorders, hypotonia, seizures, and talipes. We report on a patient with microcephaly and trigonocephaly, moderate intellectual disability, speech and languag…

0301 basic medicinePediatricsmedicine.medical_specialtyMicrocephalyLanguage delayDevelopmental delayTrigonocephaly030105 genetics & heredityTooth anomaliesXp22.31 duplication03 medical and health sciencesGene duplicationIntellectual disabilityGeneticsmedicineTrigonocephalyTooth anomaliePathologicalGenetics (clinical)business.industrymedicine.diseaseHypotoniaAutism spectrum disorderNovel Insights from Clinical PracticeMicrocephalymedicine.symptombusiness
researchProduct

Next-generation sequencing in clinical practice: from the patients' preferences to the informed consent process

2016

International audience

0301 basic medicineProcess (engineering)Pilot Projects030105 genetics & heredityNext-generation sequencing NGS03 medical and health sciencesRare Diseasespréférences de spatientsNursingInformed consentHumans[ SHS.ECO ] Humanities and Social Sciences/Economies and financessequençage haut-débitComputingMilieux_MISCELLANEOUSIncidental FindingsInformed ConsentPublic Health Environmental and Occupational HealthHigh-Throughput Nucleotide SequencingPatient PreferenceGeneral Medicineinformed consent processFocus Groups[SHS.ECO]Humanities and Social Sciences/Economics and Financeconsentement informéFocus groupPatient preferenceClinical Practicepatients' preferencesPsychology
researchProduct

Exosomes as diagnostic and predictive biomarkers in lung cancer

2017

The concept of exosomes has evolved from be considered garbage bags to the demonstration that exosomes could play very interesting roles and functions, from biomarkers detection to the potential of work as drug delivery systems. It has been widely proved that exosomes can contain key molecules important for the tumour development. The current review summarizes the latest investigations developed in the field of predictive exosomal biomarkers. The microRNAs (miRNAs) are the more known molecules due to their amount inside the exosomes and the sensitivity of the techniques available for their study. However, exosomal proteins, RNA and DNA are becoming an interesting and more feasible field of …

0301 basic medicinePulmonary and Respiratory MedicineNon-small cell lung cancer (NSCLC)Review ArticleBioinformaticsExosomes03 medical and health sciencesliquid biopsies0302 clinical medicineLiquid biopsiemicroRNAmedicineLung cancerPredictive biomarkerdrug resistanceBiomarkers; Drug resistance; Exosomes; Liquid biopsies; Non-small cell lung cancer (NSCLC); Pulmonary and Respiratory Medicinebusiness.industrybiomarkersBiomarkermedicine.diseaseMicrovesiclesClinical PracticeExosomenon-small cell lung cancer (NSCLC)030104 developmental biologyTumour development030220 oncology & carcinogenesisDrug resistanceHuman medicinebusiness
researchProduct

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

2020

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called “incretin-based therapies” (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome trials (CVOTs) have provided useful information that has helped to shape changes in clinical practice guidelines for the management of T2DM. At the same time, the mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of these medications are still being explored. A summary of the main findings from CVOTs performed to-date with particular emphasis on vari…

0301 basic medicineendocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 4Endocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismClass effectBody weightCardiovascular SystemIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineType 2 diabetes mellitusmedicineAnimalsHumansIntensive care medicineGlucagon-like peptide 1 receptorDipeptidyl-Peptidase IV Inhibitorsbusiness.industryDPP-4 Inhibitorsdigestive oral and skin physiologyType 2 Diabetes MellitusCardiovascular riskDPP4- inhibitorClinical Practice030104 developmental biologyCardiovascular DiseasesGlucagon-like peptide 1 receptor agonistbusinessCardiovascular outcomesMetabolism
researchProduct

Biomarkers of Oxidative Stress for Neonatal Lung Disease

2021

The transition from prenatal to postnatal life causes a significant increase in arterial oxygen tension and the activation of metabolic pathways enabling the newborn's adaptation to the extra-uterine environment. The balance between pro-oxidant and anti-oxidant systems is critical to preserve cellular functions. Indeed, oxidative stress (OS) occurs when the production of free radicals is not balanced by the activity of intracellular antioxidant systems, contributing to cellular and tissue damage. Perinatal OS may have serious health consequences during the postnatal period and later in life. Namely, OS has been recognized as the major cause of lung injury in newborns, especially those prete…

0301 basic medicinelung diseaseMini ReviewDiseaseLung injuryBioinformaticsmedicine.disease_causePediatrics03 medical and health sciences0302 clinical medicinenewbornMedicineoxidative stressoxidative streLungHealth consequencesbusiness.industryprematuritylcsh:RJ1-570lcsh:PediatricsClinical Practice030104 developmental biologymedicine.anatomical_structurePediatrics Perinatology and Child HealthBiomarker (medicine)biomarkerbusinessNeonatal lung030217 neurology & neurosurgeryOxidative stress
researchProduct

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO…

2017

The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account t…

0301 basic medicinemedicine.medical_specialtyChinaColorectal cancerDrug availabilityEthnic groupTaiwanConsensuSystemic therapyScientific evidence03 medical and health sciences0302 clinical medicineAsian PeopleRepublic of KoreaAsian countrymedicineHumansNeoplasm MetastasisReimbursementClinical OncologyClinical practice guidelinePan-Asianbusiness.industryMalaysiaHematologymedicine.diseaseColorectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicinebusinessColorectal NeoplasmsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: …

2020

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treat…

0301 basic medicinemedicine.medical_specialtyESMO guidelinesDrug availability03 medical and health sciences0302 clinical medicineAdvanced diseaseAsian countryconsensuMedicineHCCReimbursementESMO guidelinePan-Asianbusiness.industryCancer conferenceRelapsed Hepatocellular CarcinomaHematologyhepatocellular carcinomaClinical Practice030104 developmental biologyOncologyconsensus030220 oncology & carcinogenesisFamily medicinebusiness
researchProduct

The forgotten tale of Brazilian phage therapy

2020

The use of bacteriophages to treat bacterial infections (known as phage therapy) is considered a possible solution to the antimicrobial resistance crisis. However, phage therapy is not a new concept. The discovery of phages in the early 20th century was closely tied to clinical practice, and phage therapy quickly spread around the world. The use of phage therapy in South America in the previous century is still shrouded in mystery and has been mentioned only briefly in recent scientific literature. Research on Brazilian reference collections of medical texts showed that Brazil was an important, but so far little-known, player of phage therapy, uncovering interesting priority claims and miss…

0301 basic medicinemedicine.medical_specialtybacteriophagesphage therapybakteeritauditHistoryPhage therapyvirusesmedicine.medical_treatment030106 microbiologyStaphylococcal infectionsbakteriofagit03 medical and health sciencesAntibiotic resistanceoppihistoriamedicineHumansBacteriophagesPhage TherapytutkimushistoriaBacillary dysenteryBacterial Infectionsmedicine.diseasefagiterapiaClinical Practice030104 developmental biologyInfectious Diseasesbacterial infectionsFamily medicineBrasiliaBrazilThe Lancet Infectious Diseases
researchProduct

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

2021

Summary Non-invasive tests are increasingly being used to improve the diagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis, focusing on the topics for which relevant evidence has been published in the last 5 years.

0301 basic medicinemedicine.medical_specialtyelastographyCirrhosisHepatologydecompensationbusiness.industrycirrhosisNon invasiveMEDLINENASHmedicine.diseaseClinical Practice03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicinemedicine030211 gastroenterology & hepatologyDecompensationIntensive care medicinebusinessserum markers of fibrosiscirrhosis decompensation elastography NASH serum markers of fibrosis
researchProduct